DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Drew Y.
Phase II study of olaparib plus durvalumab and bevacizumab (MEDIOLA): initial results in patients with non-germline BRCA-mutated platinum sensitive relapsed ovarian cancer. ESMO 2020.
Ann Oncol 2020;
31 (Suppl. 04) S615-S616
DOI: 10.1016/j.annonc.2020.08.953.
We do not assume any responsibility for the contents of the web pages of other providers.